OBJECTIVE: To investigate the application status and trend of anti-HIV drugs in outpatient department of this hospital

and analyze the application rationality. METHODS: Retrospective analysis method was performed to analyze the number

gender

age and frequency of visits of AIDS patients

patients with pre-exposure prevention and post-exposure blockade of HIV infection in outpatient department of the hospital from 2016 to 2020. According to the defined daily dose method recommended by WHO

defined daily dose system（DDDs）

consumption sum of self-paid drugs

defined daily cost（DDC） and consumption sum ranking/DDDs ranking（B/A） of all anti-HIV drugs in this hospital were analyzed and evaluated. RESULTS: From 2016 to 2019

the number of outpatients in this hospital for AIDS patients and patients with pre-exposure prevention and post-exposure blockade of HIV infection increased year by year

and decreased slightly in 2020. From 2016 to 2020

among the anti-HIV drugs in outpatient department of this hospital

the top five drugs ranked by DDDs were tenofovir

lamivudine

efavirenz

lopinavir

ritonavir and and zidomivir divudine

all of which were national free drugs

and the DDDs of tenofovir

lamivudine and efavirenz ranked the top three. The DDDs of self-paid drugs were relatively low

and the DDDs of some self-paid drugs increased in 2019

such as emtricitabine and tenofovir

and rilpivirine. The dosage and DDDs of elvitegravir

cobicistat

emtricitabine and tenofovir alafenamide fumarate increased significantly in 2020. The DDC of self-paid drugs was higher

ranging from 40 yuan to 96 yuan

of which the DDC of rilpivirine was 40 yuan

and the DDC of dotiabalamib was 96 yuan; the B/A of self-paid drugs were <1. CONCLUSIONS: The varieties of anti-HIV drugs in outpatient department of the hospital can basically meet the clinical needs

and the application of anti-HIV drugs is basically reasonable.